Increase in chronic and lifestyle-associated diseases to Brazil market sales
Brazil has emerged as a manufacturing hub for pharmaceutical and biotechnology companies, with the pharma market forecast to grow from $12.4 billion in 2007 to $58.8 billion in 2020, at a compound annual growth rate (CAGR) of 12.7%, says research and consulting firm GlobalData.
Joshua Owide, director of Healthcare Industry Dynamics, says: “The health care market in Brazil is primarily driven by an increase in disease burden, affordability, and access to primary care. However, healthcare does not cover the total population and therefore restricts further market growth.”
In fact, the Brazilian health care system comprises of two subsystems: public and private. The country’s private health care insurance system is the second largest in the world, covering approximately 23.7% of the population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze